StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma approves 1-for-10 reverse stock split for Nasdaq October 22, 2026 4:24 PM - StreetInsider CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans October 22, 2026 4:24 PM - Globe NewsWire Propanc Biopharma executes 1-for-10 reverse stock split on Nasdaq October 22, 2026 8:30 AM - StreetInsider Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans October 22, 2026 8:30 AM - StreetInsider Form DEF 14C Propanc Biopharma, Inc. For: Oct 20 October 21, 2026 9:23 AM - SEC Filing Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells October 16, 2026 8:36 AM - Globe NewsWire Propanc Biopharma publishes pilot study on cancer proenzyme formula October 14, 2026 8:31 AM - StreetInsider Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer October 14, 2026 8:30 AM - Globe NewsWire Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer October 14, 2026 8:30 AM - StreetInsider Form PRE 14C Propanc Biopharma, Inc. For: Oct 08 October 8, 2026 5:26 PM - SEC Filing Propanc reports preclinical PRP data for pancreatic cancer treatment October 7, 2026 8:30 AM - StreetInsider Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib October 7, 2026 8:30 AM - StreetInsider Form S-1 Propanc Biopharma, Inc. October 5, 2026 5:16 PM - SEC Filing Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss September 29, 2026 8:32 AM - StreetInsider Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results September 29, 2026 8:30 AM - Globe NewsWire Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results September 29, 2026 8:30 AM - StreetInsider Form 10-K Propanc Biopharma, Inc. For: Jun 30 September 25, 2026 5:09 PM - SEC Filing Propanc releases preclinical PDAC data for PRP, eyes 2027 trial September 22, 2026 8:31 AM - StreetInsider Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 September 22, 2026 8:30 AM - StreetInsider Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. September 16, 2026 8:30 AM - StreetInsider Propanc Biopharma plans Phase 1b cancer drug trial for February 2027 September 9, 2026 8:30 AM - StreetInsider Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 September 9, 2026 8:30 AM - StreetInsider Propanc reports preclinical pancreatic cancer data for PRP drug candidate August 27, 2026 8:30 AM - StreetInsider Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit August 27, 2026 8:30 AM - Globe NewsWire Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit August 27, 2026 8:30 AM - StreetInsider Form DEF 14C Propanc Biopharma, Inc. For: Aug 20 August 21, 2026 6:02 AM - SEC Filing Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia August 18, 2026 8:30 AM - StreetInsider Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP August 18, 2026 8:30 AM - StreetInsider Propanc Biopharma plans Phase 1b trial for cancer drug PRP August 12, 2026 8:32 AM - StreetInsider Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers August 12, 2026 8:30 AM - StreetInsider Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer August 6, 2026 8:31 AM - StreetInsider Propanc Biopharma reports preclinical data showing 90% tumor inhibition August 6, 2026 8:31 AM - StreetInsider Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Model August 6, 2026 8:30 AM - Globe NewsWire Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models August 6, 2026 8:30 AM - StreetInsider Propanc Biopharma completes $500K first tranche of share buyback August 5, 2026 8:30 AM - StreetInsider Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program August 5, 2026 8:30 AM - StreetInsider Form PRE 14C Propanc Biopharma, Inc. For: Aug 04 August 5, 2026 6:01 AM - SEC Filing Form EFFECT Propanc Biopharma, Inc. July 28, 2026 6:05 AM - SEC Filing Full Article List